CCA
RUBY

Catalyst Capital Advisors’s Rubius Therapeutics, Inc RUBY Stock Holding History

Catalyst Capital Advisors’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-250
Closed -$6K – 511
2018
Q3 		$6K Buy
+250
New +$5.72K ﹤0.01% 395

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Catalyst Capital Advisors's RUBY Position: Q4 2018 in Review

Catalyst Capital Advisors sold out of Rubius Therapeutics, Inc (RUBY) in Q4 2018, closing a stake of 250 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in RUBY in Q3 2018 and held it in 1 quarter. The position peaked at $6K in Q3 2018. 57 funds tracked by Wall St. Rank hold RUBY as of Q4 2018.

  • Catalyst Capital Advisors reported no remaining Rubius Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 250 Rubius Therapeutics, Inc shares in Q4 2018, an estimated $6K.
  • Catalyst Capital Advisors first reported a position in Rubius Therapeutics, Inc in Q3 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Rubius Therapeutics, Inc position peaked at $6K in Q3 2018.
  • 57 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q4 2018.

Based on Catalyst Capital Advisors's 13F filing for Q4 2018, filed 7 Feb 2019.